Withdrawn ID: | 709 |
---|---|
Canonical SMILES: | |
Standard InChI: | |
Standard InChIKey: | |
ATC class(es): | P01BX01 |
Molecular Formula: | C26H30Cl2F3NO |
Molweight: | 500.424 |
Withdrawn due to drug safety reasons: | No |
---|---|
First approved: | 1992 |
Total reported cases (submitted by medical professionals) with Halofantrine as primary suspect: | 7 |
---|
Death: | 5 |
---|---|
Hospitalization (initial or prolonged): | 3 |
Side-effect | Case number |
---|---|
TORSADE DE POINTES | 2 |
THROMBOCYTOPENIA | 2 |
VENTRICULAR TACHYCARDIA | 2 |
SUPRAVENTRICULAR TACHYCARDIA | 2 |
ANAEMIA MACROCYTIC | 2 |
BLOOD PRESSURE SYSTOLIC DECREASED | 2 |
CARDIAC ARREST | 2 |
MALAISE | 2 |
LOSS OF CONSCIOUSNESS | 2 |
CARDIAC FAILURE | 2 |
CIRCULATORY COLLAPSE | 2 |
ELECTROCARDIOGRAM QT PROLONGED | 2 |
ABDOMINAL PAIN UPPER | 1 |
ARRHYTHMIA | 1 |
CONVULSION | 1 |
DEATH | 1 |
DYSPNOEA | 1 |
EYE MOVEMENT DISORDER | 1 |
FLATULENCE | 1 |
FOAMING AT MOUTH | 1 |
MYOCARDIAL INFARCTION | 1 |
NAUSEA | 1 |
RESTLESSNESS | 1 |
SUDDEN DEATH | 1 |
SYNCOPE | 1 |
Target UniProtKB ID | Activity in nm | Target Name | Target gene |
---|---|---|---|
Q12809 | 40 | Potassium voltage-gated channel subfamily H member 2 | KCNH2_HUMAN |
Toxicity class: | 4 |
---|---|
Toxicity type: | N/A |
LD50: | 1932.5 mg/kg |
ChEBML: | CHEMBL1107 |
---|---|
DrugBank: | DB01218 |